ArticleFrontiers in plant science2022
A DNA-Free Editing Platform for Genetic Screens in Soybean
Article in Frontiers in plant science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- AI-Guided DNA-Free and Genotype-Independent Genome Editing for Soybean Improvement.Plants (Basel, Switzerland) · 2026Review
- Beyond GMOs: transgene-free gene-edited crops for global food security.Frontiers in plant science · 2026Review
- CRISPR/Cas9 in soybean research: a measured leap toward genetic refinement.Frontiers in genome editing · 2026Review
- A visual monitoring DNA-free multi-gene editing system excised via LoxP::FRT/FLP in poplar.Plant biotechnology journal · 2025Article
- CRISPR/Cas-Mediated Optimization of Soybean Shoot Architecture for Enhanced Yield.International journal of molecular sciences · 2025Review
- CRISPR/Cas system-mediated transgene-free or DNA-free genome editing in plants.TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik · 2025Review
- CRISPR/Cas genome editing in soybean: challenges and new insights to overcome existing bottlenecks.Journal of advanced research · 2025Review
- CRISPR-based gene editing in plants: Focus on reagents and their delivery tools.BioImpacts : BI · 2025Review
- Establishment of efficient hypocotyl-derived protoplast isolation and its application in soybean (Frontiers in plant science · 2025Article
- Enhancing genetic modification in recalcitrant plants: An investigation in chili (Plant biotechnology (Tokyo, Japan) · 2024Article
- Review
- Advances inFrontiers in plant science · 2024Article
- Establishment of targeted mutagenesis in soybean protoplasts using CRISPR/Cas9 RNP delivery via electro-transfection.Frontiers in plant science · 2023Article
- Genome-wide characterization of the soybean DOMAIN OF UNKNOWN FUNCTION 679 membrane protein gene family highlights their potential involvement in growth and stress response.Frontiers in plant science · 2023Article
- Plant biomacromolecule delivery methods in the 21st century.Frontiers in genome editing · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRISPR/Cas9-based ribonucleoprotein (RNP)-mediated system has the property of minimizing the effects related to the unwanted introduction of vector DNA and random integration of recombinant DNA. Here, we describe a platform based on the direct delivery of Cas9 RNPs to soybean protoplasts for genetic screens in knockout gene-edited soybean lines without the transfection of DNA vectors. The platform is based on the isolation of soybean protoplasts and delivery of Cas RNP complex. To empirically test our platform, we have chosen a model gene from the soybean genetic toolbox. We have used five different guide RNA (gRNA) sequences that targeted the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.